Concert Pharmaceuticals, Inc. (CNCE) |
| 8.37 0 (0%) 03-03 16:00 |
| Open: | 8.38 |
| High: | 8.55 |
| Low: | 8.35 |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | -2.64 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 37.14 |
| Resistance 1: | 31.80 |
| Pivot price: | 30.33 |
| Support 1: | 28.72 |
| Support 2: | 26.82 |
| 52w High: | 8.55 |
| 52w Low: | 2.72 |
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Financials
| EPS | 2.490 |
| Book Value | 27.860 |
| PEG Ratio | 1.06 |
| Gross Profit | 9.222 |
| Profit Margin (%) | 24.19 |
| Operating Margin (%) | 50.86 |
| Return on Assets (ttm) | 0.9 |
| Return on Equity (ttm) | 8.9 |
Company news
Thu, 28 Mar 2024
Concert Pharmaceuticals (NASDAQ: CNCE) - Share Price - intelligentinvestor.com.au
Wed, 15 Feb 2023
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata - Business Wire
Thu, 19 Jan 2023
Sun Pharma to Acquire Concert Pharmaceuticals - citybiz
Thu, 19 Jan 2023
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata - Business Wire
Mon, 23 May 2022
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata - Business Wire
Sat, 05 Dec 2020
Concert Pharmaceuticals Stock Price Forecast. Should You Buy CNCE? - StockInvest.us
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
